67.76
2.97 (4.58%)
| Penutupan Terdahulu | 64.79 |
| Buka | 64.79 |
| Jumlah Dagangan | 902,926 |
| Purata Dagangan (3B) | 970,372 |
| Modal Pasaran | 2,973,511,936 |
| Harga / Pendapatan (P/E Ke hadapan) | 106.38 |
| Harga / Jualan (P/S) | 4.71 |
| Harga / Buku (P/B) | 7.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | -44.91% |
| Margin Operasi (TTM) | -33.55% |
| EPS Cair (TTM) | -2.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 183.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.13% |
| Nisbah Semasa (MRQ) | 5.57 |
| Aliran Tunai Operasi (OCF TTM) | -65.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -16.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tarsus Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.33 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.25% |
| % Dimiliki oleh Institusi | 110.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 2,562,154 |
| Jennison Associates Llc | 30 Jun 2026 | 1,663,655 |
| Tang Capital Management Llc | 31 Mar 2026 | 1,188,624 |
| Assenagon Asset Management S.A. | 30 Jun 2026 | 947,495 |
| Driehaus Capital Management Llc | 31 Mar 2026 | 926,125 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |